KDST Stock Overview
A biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kadimastem Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪13.03 |
| 52 Week High | ₪15.65 |
| 52 Week Low | ₪4.30 |
| Beta | 0.35 |
| 1 Month Change | 1.80% |
| 3 Month Change | 116.09% |
| 1 Year Change | 113.26% |
| 3 Year Change | -61.09% |
| 5 Year Change | -73.02% |
| Change since IPO | -97.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| KDST | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 9.3% | 0.3% | -1.9% |
| 1Y | 113.3% | -23.6% | 21.8% |
Return vs Industry: KDST exceeded the IL Biotechs industry which returned -23.6% over the past year.
Return vs Market: KDST exceeded the IL Market which returned 21.8% over the past year.
Price Volatility
| KDST volatility | |
|---|---|
| KDST Average Weekly Movement | 16.2% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IL Market | 8.5% |
| 10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: KDST's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: KDST's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 12 | Ronen Twito | www.kadimastem.com |
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
Kadimastem Ltd Fundamentals Summary
| KDST fundamental statistics | |
|---|---|
| Market cap | ₪54.64m |
| Earnings (TTM) | -₪9.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.6x
P/E RatioIs KDST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KDST income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪9.72m |
| Earnings | -₪9.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -83.8% |
How did KDST perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 02:16 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kadimastem Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|